Astellas Venture Management

Astellas Venture Management is a California-based financial organization that targets investments in the biotechnology sector.

Business Model:

Revenue: $5.7M

Employees: 2-10

Rankings

Detailed Astellas Venture Management Information

Geographic Data

Astellas Venture Management headquarters map

Address: 2882 Sand Hill Road Suite 121

City: Menlo Park

State: CA

Zip: 94025

Country: US

Financial Info

Stage:

Raised Last:

$0

Raised Total:

$0

Metrics

0Website Global Rank

0Website Monthly Traffic

Twitter Followers

Description

AVM is a venture capital firm focusing on human therapeutics field.

Contact Phone:
+16504946000

Contact Email:

Announced Date Company Transaction Money Raised
3/2021 NeoPhore Series B 0
12/2014 Crescendo Biologics Venture Round -
9/2018 Twentyeight-Seven Therapeutics Series A 65M
8/2008 F2G Venture Round 11.8M
1/2011 PanOptica Series A 30M
7/2009 Viamet Pharmaceuticals Series B 25M
10/2009 Evolva Series B 27.8M
10/2014 Viamet Pharma Series D 60M
6/2022 Carbon Biosciences Series A 0
2/2021 Orna Therapeutics Series A 0
9/2020 Fukushima SiC Applied Engineering Series C 0
6/2012 PhaseBio Pharmaceuticals Series B 23M
8/2020 Trishula Therapeutics Funding Round -
12/2013 Crescendo Biologics Series A 28.5M
8/2007 Nereus Pharmaceuticals Series D 0
9/2010 DecImmune Therapeutics Venture Round 3.2M
12/2016 Trieza Therapeutics Pre Seed Round -
6/2008 Inimex Pharmaceuticals Series B 22M
4/2022 Turn.bio Venture Round -
1/2023 NeoPhore Series B 0
8/2016 Cleave Therapeutics Series B 0
11/2011 Cleave Therapeutics Series A 42M
8/2019 Cleave Therapeutics Series C 0
5/2013 Effector Therapeutics Series A 45M
11/2019 Heartseed Series B 0
6/2010 Nereus Pharmaceuticals Series E 0
7/2011 Verastem Oncology Series B 32M
5/2021 Mogrify Series A 0
4/2014 Crescendo Biologics Series A 3.3M
12/2012 Bicycle Therapeutics Venture Round 6M
11/2022 Casma Therapeutics Series C 46M
3/2021 PhoreMost Series B 45.3M
10/2014 Bicycle Therapeutics Series A 32M
1/2009 Intradigm Corporation Series B 0
10/2014 Raze Therapeutics Series A 24M
11/2020 Catamaran Bio Series A 0
11/2009 Fate Therapeutics Series B 30M
11/2019 CODA Biotherapeutics Series A 15M
1/2016 Tizona Therapeutics Series A 27M
10/2009 Epizyme Series B 32M
5/2019 Twentyeight-Seven Therapeutics Series A 15M
12/2015 Effector Therapeutics Series B 40M
2/2006 Lectus Therapeutics Series A 14.3M
6/2022 DEM BioPharma Series A 0
7/2017 Effector Therapeutics Series C 38.6M
8/2019 Oncorus Series B 0
12/2016 Oncorus Series A 5M
9/2012 F2G Equity 30M
9/2018 CODA Biotherapeutics Series A 19M
5/2011 Fate Therapeutics Series B 36M
2/2023 Avilar Therapeutics Seed Round 0
7/2018 Heartseed Series A 7.2M
2/2013 DecImmune Therapeutics Venture Round 2.3M
1/2020 TScan Therapeutics Series B 35M
3/2016 Tizona Therapeutics Series B 43M
9/2006 CoMentis Series B 50M
3/2006 F2G Venture Round 8.7M
6/2022 DEM BioPharma Series A 0
6/2022 Carbon Biosciences Series A 0
4/2022 Turn.bio Venture Round -
5/2021 Mogrify Series A 0
3/2021 PhoreMost Series B 0
3/2021 NeoPhore Series B 0
2/2021 Orna Therapeutics Series A 0
11/2020 Catamaran Bio Series A 0
9/2020 Fukushima SiC Applied Engineering Series C 0
8/2020 Trishula Therapeutics Funding Round -

Startup Industries

Startup Locations

Portfolio Current Status

Portfolio Employee Count

Name Price
Name Size Announced Date

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research